Predicting VTE in multiple myeloma, azithromycin promotes relapse after HSCT, and dual antigen targeted NK cells in B cell malignancies
Blood Podcast
00:00
I-Duo NK Cells Show Durable Response and Prevent Antigen Escape in Lymphoma and Leukemia
Up to 50% of all patients receiving anti-CD19 CAR T cell therapy will relapse within the first year. There is an unmet need for new therapies that can prevent tumor antigen escape. A better understanding of the interplay between these factors could help identify novel therapeutic targets.
Transcript
Play full episode
